ZAGENO
25.5.2023 14:01:43 CEST | ACCESS Newswire | Press release
ZAGENO Empowers Life Science Research with Unparalleled Efficiency and Cost Savings
CAMBRIDGE, MA / ACCESSWIRE / May 25, 2023 / ZAGENO, the leading online marketplace for life science research products, announces the completion of a $33 million funding round. General Catalyst, the largest public pension fund in the United States, Grazia Equity, OakRidge Management Group, and a German investment house led this round, joined by existing investors Capnamic Ventures and HighSage Ventures.
This funding propels ZAGENO's expansion in the United States and Europe, significantly enhancing the accessibility and affordability of life science research products. ZAGENO simplifies product discovery, experiment planning, and seamless purchasing from thousands of suppliers. The marketplace revolutionizes the scientific workflow, saving time and product costs. With a wide selection of quality products and verified suppliers, scientists benefit from competitive pricing fostered by the marketplace's transparency and supplier choice.
"We're thrilled to welcome new investors, including one of America's most powerful shareholder bodies and global leader in the investment industry and a prominent German investment house, while enjoying continued support from General Catalyst and existing investors," said Florian Wegener, CEO of ZAGENO. "This funding empowers scientists to focus on scientific value creation."
ZAGENO's online marketplace offers a vast selection of products and services, including laboratory equipment, consumables, chemicals, antibodies, and customized solutions. By providing scientists access to a network of verified suppliers, the ZAGENO platform enables informed purchasing decisions.
"ZAGENO is transforming the scientific research industry with its groundbreaking platform," said Larry Bohn, Managing Partner at General Catalyst. "We proudly support their journey."
"With this funding, ZAGENO is positioned to deliver even greater value to scientists worldwide," emphasized Joe von Rickenbach, Chairman of the Board of ZAGENO. "Their innovative platform drives unmatched efficiency and cost savings."
ZAGENO is primed for rapid growth and pioneering innovation in the scientific research industry with this new funding.
To learn more about ZAGENO, please visit www.zageno.com.
About ZAGENO
ZAGENO is a marketplace for life science research products. By revolutionizing how scientists discover, procure, and manage life science research products, ZAGENO supports researchers pursuing breakthroughs that improve our lives. With an extensive catalog, advanced search functionality, transparent pricing, and dedicated customer support, ZAGENO simplifies the research workflow and enables scientists to focus on groundbreaking discoveries. ZAGENO is a global company with offices in Cambridge, San Francisco, Berlin, and Bangalore. For more information, visit www.zageno.com.
About General Catalyst
General Catalyst is a venture capital firm that invests in powerful, positive change that endures - for our entrepreneurs, our investors, our people, and society. We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond to build companies that withstand the test of time. With offices in San Francisco, Palo Alto, New York City, London, and Boston, the firm has helped support the growth of businesses such as: Airbnb, Deliveroo, Guild, Gusto, Hubspot, Illumio, Lemonade, Livongo, Oscar, Samsara, Snap, Stripe, and Warby Parker. For more: www.generalcatalyst.com.
Contact Information
Stephanie Harold
pr@zageno.com
+1 (857) 477-8479
Related Files
Related Images
SOURCE: ZAGENO
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/757107/ZAGENO-Secures-33M-Funding-to-Revolutionize-Life-Science-Research-Procurement
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom